Meeting
2018 ASCO Annual Meeting
A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.
Authors
Saad Zafar Usmani
Levine Cancer Institute, Charlotte, NC
Saad Zafar Usmani , Fredrik Schjesvold , Albert Oriol Rocafiguera , Lionel Karlin , Robert M. Rifkin , Habte Aragaw Yimer , Richard LeBlanc , Naoki Takezako , Robert Donald McCroskey , Kenshi Suzuki , Michele Cavo , Thierry Facon , Sundar Jagannath , Sagar Lonial , Razi Ghori , Mohammed Z.H. Farooqui , Jason Liao , Patricia Marinello , Jesus San-Miguel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT02579863
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8010)
DOI
10.1200/JCO.2018.36.15_suppl.8010
Abstract #
8010
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).
First Author: Saad Zafar Usmani
Poster
2018 ASCO Annual Meeting
Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM).
First Author: Robert Z. Orlowski
Poster
2015 ASCO Annual Meeting
Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).
First Author: Meletios A. Dimopoulos
Poster
2014 ASCO Annual Meeting
![MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.](https://d201v5jt9ylckg.cloudfront.net/144/8608/96164/96164_poster_pv.jpg)
MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.
First Author: Paul G. Richardson